|
| Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA082723-09
|
|
K Vitamins- A New Class of Liver Cell Growth Inhibitors
|
CARR, BRIAN
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$263,832
|
|
Chronic Liver Disease and Cirrhosis
|
NIDA
|
1K23DA020383-01A1
|
|
Buprenorphine as a Bridge to HCV Treatment for HIV/HCV Coinfected Opioid Users
|
TAYLOR, LYNN
|
MIRIAM HOSPITAL
|
RI
|
$179,212
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5F32DK074348-02
|
|
Hepatoxicity in an African HIV Treatment Cohort
|
HOFFMANN, CHRISTOPHER
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$53,992
|
|
Chronic Liver Disease and Cirrhosis
|
NIDA
|
1R01DA021550-01A2
|
|
HCV Transmission among Young IDUs in NYC
|
EDLIN, BRIAN
|
SUNY DOWNSTATE MEDICAL CENTER
|
NY
|
$834,452
|
|
Chronic Liver Disease and Cirrhosis
|
NIEHS
|
5R01ES014626-02
|
|
Regulation of Sulfotransferases by LXR and its Implication in Pathophysiology
|
XIE, WEN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$308,157
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI047365-09
|
|
Structure and Function of the Hepatitis C Virus Genome
|
SARNOW, PETER
|
STANFORD UNIVERSITY
|
CA
|
$362,764
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
2R01AI020001-25
|
|
Pathogenesis of Liver Disease in Hepatitis
|
CHISARI, FRANCIS
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$685,357
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K08DK066040-05
|
|
Engineering Embryonic Stem Cell Differentiation into Hepatocytes
|
TILLES, ARNO
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$118,081
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5F31AA016710-02
|
|
Characterizing the role of peroxiredoxin 6 in Alcoholic Liver Disease.
|
ROEDE, JAMES
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$27,343
|
|
Chronic Liver Disease and Cirrhosis
|
NIEHS
|
5R01ES012752-05
|
|
Cellular Roles in Liver Pathology: Dioxin as Prototype
|
BRADFIELD, CHRISTOPHER
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$428,593
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI057591-04
|
|
Alteration of innate immunity by HCV core
|
HAHN, YOUNG
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$282,356
|
|
Chronic Liver Disease and Cirrhosis
|
NIEHS
|
5R01ES007800-12
|
|
Ah Receptor Anatomy: Implications for Dioxin Toxicity
|
ELFERINK, CORNELIS
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$330,706
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA124648-02
|
|
An integrative approach to cancer gene discovery in hepatocellular carcinoma
|
POWERS, SCOTT
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$419,084
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK066387-05
|
|
Modifiers of a Mouse Model of Alagille Syndrome
|
GRIDLEY, THOMAS
|
JACKSON LABORATORY
|
ME
|
$523,513
|
|
Chronic Liver Disease and Cirrhosis
|
NHLBI
|
5R01HL051586-15
|
|
Animal Models for Lipid Metabolism and Atherosclerosis
|
CHAN, LAWRENCE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$364,125
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R37AI047367-09
|
|
HCV-specific T cell response
|
WALKER, CHRISTOPHER
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$541,702
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK048252-15
|
|
Pathophysiology of Distal Tyrosine Pathway Disorders
|
GROMPE, MARKUS
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$308,500
|
|
Chronic Liver Disease and Cirrhosis
|
NIGMS
|
5R01GM041840-20
|
|
Copper Homeostasis in Yeast
|
THIELE, DENNIS
|
DUKE UNIVERSITY
|
NC
|
$318,324
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5F32DK067781-03
|
|
Cis- and Trans-acting Factors in HCV Gene Expression
|
BRADRICK, SHELTON
|
DUKE UNIVERSITY
|
NC
|
$52,048
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK063308-06
|
|
Regulation of Stellate Cell Contractility
|
ROCKEY, DON
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$342,836
|
|
Chronic Liver Disease and Cirrhosis
|
NIMH
|
5R01MH079752-02
|
|
Role of evolving white matter damage in neurocognitive effects of HIV and HCV
|
JERNIGAN, TERRY
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$347,625
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI072613-02
|
|
Identification and characterization of cellular factors involved in HCV entry
|
RICE, CHARLES
|
ROCKEFELLER UNIVERSITY
|
NY
|
$414,473
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI067417-03
|
|
Molecular Modulation of HBV Capsid Assembly
|
ZLOTNICK, ADAM
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$345,885
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5F31AA016434-02
|
|
Thioredoxin and ethanol-induced liver injury
|
COHEN, JESSICA
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
OH
|
$26,930
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI065985-03
|
|
Defining NS4B Function in Hepatitis C Virus Replication
|
BLIGHT, KERIL
|
WASHINGTON UNIVERSITY
|
MO
|
$289,575
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK064223-05
|
|
HCV NS5A: Molecular Virology and Antiviral Target
|
GLENN, JEFFREY
|
STANFORD UNIVERSITY
|
CA
|
$261,667
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5F32CA111040-03
|
|
Modulation of Hepatic N-Myristoyltransferases by Dioxins
|
WORMKE, MARK
|
NATL RESEARCH CTR/ENVIRONMENT & HEALTH
|
GERM
|
$45,048
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA106280-04
|
|
Prostaglandin Signaling Pathway in Liver Cancer
|
WU, TONG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$224,802
|
|
Chronic Liver Disease and Cirrhosis
|
NIMH
|
5R01MH070553-04
|
|
Cytokine-CRH Interactions in IFN-alfa-Induced Depression
|
RAISON, CHARLES
|
EMORY UNIVERSITY
|
GA
|
$326,412
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK064366-05
|
|
A Promoter-Specific TFO Prevents Liver Fibrosis
|
GUNTAKA, RAMAREDDY
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
TN
|
$268,618
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA007846-18
|
|
Effects of Ethanol on Endocytosis in the Liver
|
CASEY, CAROL
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$215,048
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK062277-05
|
|
Role of Wnt/Beta-Catenin Signaling in Liver Development
|
MONGA, SATDARSHAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$218,911
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R37AI028731-19
|
|
Noncarbohydrate Approaches to AntiAIDS Nuleosides
|
LIOTTA, DENNIS
|
EMORY UNIVERSITY
|
GA
|
$324,651
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK066266-05
|
|
Long-term Outcome: Transplant for Alcohol Liver Disease
|
DIMARTINI, ANDREA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$259,419
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI061158-04
|
|
Mechanisms of Innate and Adaptive Immunity In HCV
|
NELSON, DAVID
|
UNIVERSITY OF FLORIDA
|
FL
|
$304,514
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA039416-23
|
|
Molecular Mechanisms of Chemoprevention: Dithiolethiones
|
KENSLER, THOMAS
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$502,144
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK056966-06
|
|
Role of Tissue Micro-Architecture on Hepatocyte Function
|
BHATIA, SANGEETA
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$342,972
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA083650-09
|
|
ALTERED GROWTH FACTOR PATHWAYS IN BILIARY CANCER
|
SIRICA, ALPHONSE
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$302,232
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI043453-11
|
|
Mechanisms of Hepadnavirus Assembly and Replication
|
HU, JIANMING
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$297,279
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA014891-04
|
|
NFkB-mediated collagen regulation by SAMe in HSCs
|
SCHRUM, LAURA
|
UNIVERSITY OF NORTH CAROLINA CHARLOTTE
|
NC
|
$197,874
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI069000-03
|
|
Roles for microRNA-122 in hepatitis C virus RNA amplification
|
SARNOW, PETER
|
STANFORD UNIVERSITY
|
CA
|
$295,433
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA023931-30
|
|
Analyzing Hepatitis B Virus Pathogenesis
|
ISOM, HARRIET
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$325,985
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA100908-04
|
|
Role of Kupffer Cell in Hepatic Carcinogenesis
|
KLAUNIG, JAMES
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$226,529
|
|
Chronic Liver Disease and Cirrhosis
|
NIBIB
|
5K08EB004348-04
|
|
Percutaneous MR Guided Creation of a Meso-Caval Shunt
|
AREPALLY, ARAVIND
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$193,361
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K08DK069621-04
|
|
Mechanisms of Hepatic Steatosis Prevention
|
PUDER, MARK
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$127,683
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI069142-02
|
|
Immune Mechanisms of HCV Persistence and Pathogenesis
|
SUN, JIAREN
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$333,295
|
|
Chronic Liver Disease and Cirrhosis
|
NIDA
|
5R01DA011598-10
|
|
Nutritional Status In HIV Hispanic Drug Abusers
|
FORRESTER, JANET
|
TUFTS UNIVERSITY BOSTON
|
MA
|
$660,216
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K08DK069765-04
|
|
Apoptosis and Liver Fibrogenesis
|
TOROK, NATALIE
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$124,549
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
7R01DK066373-05
|
|
Modifiers of Iron Loading in Mice
|
ANDREWS, NANCY
|
DUKE UNIVERSITY
|
NC
|
$419,833
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R37CA023226-37
|
|
GENE EXPRESSION IN REGENERATING AND NEOPLASTIC LIVERS
|
FAUSTO, NELSON
|
UNIVERSITY OF WASHINGTON
|
WA
|
$378,690
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA010435-11
|
|
Alcohol and Liver Endothelial Cells in Immune Responses
|
THIELE, GEOFFREY
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$283,500
|
|
Chronic Liver Disease and Cirrhosis
|
NIEHS
|
1R01ES016313-01
|
|
The Environment as a Variable to Calibrate Mouse Models of Human Disease
|
ESSIGMANN, JOHN
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$544,391
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK055710-07
|
|
The plasminogen system and liver repair
|
BEZERRA, JORGE
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$301,350
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R01DK080440-01
|
|
SHP-regulation of Lipid and Lipoprotein Metabolism
|
WANG, LI
|
UNIVERSITY OF UTAH
|
UT
|
$263,375
|
|
Chronic Liver Disease and Cirrhosis
|
NIMH
|
5K23MH071177-04
|
|
Adherence to HCV Treatment in HCV and HCV/HIV Patients
|
WEISS, JEFFREY
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$148,791
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
2R01DK059615-06A1
|
|
Molecular Mechanisms of Portal Hypertension
|
SHAH, VIJAY
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$321,088
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA115625-02
|
|
Proteomic Analysis of Serum in Liver Cancer
|
GOLDMAN, RADOSLAV
|
GEORGETOWN UNIVERSITY
|
DC
|
$340,569
|
|
Chronic Liver Disease and Cirrhosis
|
NIBIB
|
5R01EB003922-02
|
|
Targeted Delivery of TFOs for Treatment of Liver Fibrosis
|
MAHATO, RAM
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
TN
|
$225,351
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
1R21AI076706-01
|
|
Impact of NK Cell Immune Pressures on HCV Evolution and Viral Fitness
|
ALTFELD, MARCUS
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$263,250
|
|
Chronic Liver Disease and Cirrhosis
|
NIEHS
|
1R03ES016368-01
|
|
Effects of Personal Exposure to Volatile Organic Compounds on Liver Function
|
WU, TIEJIAN
|
EAST TENNESSEE STATE UNIVERSITY
|
TN
|
$71,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R03DK077707-02
|
|
Early Detection and Prognosis of Patients with Hepatocellular Carcinoma
|
MARRERO, JORGE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$74,480
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK076852-02
|
|
The Lysosomal-Mitochondrial Axis in Nonalcoholic Fatty Liver Disease
|
FELDSTEIN, ARIEL
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
OH
|
$279,351
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1K23DK080145-01
|
|
Analysis of Fatty Liver in the Framingham Heart Study Cohort
|
SPELIOTES, ELIZABETH
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$185,544
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
1R21AI076834-01
|
|
Cell Culture System for Hepatitis C Virus Genotype 1a
|
DI BISCEGLIE, ADRIAN
|
SAINT LOUIS UNIVERSITY
|
MO
|
$183,750
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA109733-04
|
|
Molecular Target(s) for Interruption of HBV Infection
|
LI, JISU
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$214,052
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA121171-03
|
|
Molecular mediators of metastasis in hepatocellular carcinoma
|
LEWIS, BRIAN
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$280,074
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI065981-02
|
|
Iron and pathogenesis in infections by Vibrio vulnificus
|
CROSA, JORGE
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$377,685
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R21AI067455-02
|
|
Resolution of Acute Hepatitis B Virus Infections in Chimpanzees
|
LANFORD, ROBERT
|
SOUTHWEST FOUNDATION FOR BIOMEDICAL RES
|
TX
|
$222,579
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI069285-02
|
|
Role of TLR3 Signaling in Control of HCV
|
LI, KUI
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$126,887
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R03CA119313-02
|
|
Novel Machine Learning Methods for Analysis of MALDI-TOF Mass Spectrometry Data
|
RESSOM, HABTOM
|
GEORGETOWN UNIVERSITY
|
DC
|
$77,600
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA076541-10
|
|
Liver Regeneration as a Model for Angiogenesis
|
STOLZ, DONNA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$220,307
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA103958-05
|
|
HGF and Signaling Pathways in Hepatic Tissue Assembly
|
MICHALOPOULOS, GEORGE
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$282,995
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK066939-05
|
|
Modulation of HCV Gene Expression
|
BRANCH, ANDREA
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$370,132
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK070877-03
|
|
Immunoglobulin Allotypes in Hepatitis C Virus Infection
|
PANDEY, JANARDAN
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$186,896
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK066802-05
|
|
PATHOPHYSIOLOGY OF CRYOGLOBULINEMIC GLOMERULONEPHRITIS
|
ALPERS, CHARLES
|
UNIVERSITY OF WASHINGTON
|
WA
|
$352,173
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA015752-02
|
|
Intracellular Therapeutics for Inflammatory Liver Injury
|
HAWIGER, JACK
|
VANDERBILT UNIVERSITY
|
TN
|
$345,375
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
2R01DK064008-05
|
|
Immunologic Dysfunction in Biliary Atresia
|
BEZERRA, JORGE
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$318,750
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK050574-13
|
|
Pathogenesis of Hepatic Fibrosis and Portal Hypertension
|
ROCKEY, DON
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$314,127
|
|
Chronic Liver Disease and Cirrhosis
|
NIEHS
|
5R01ES012018-04
|
|
Ah Receptor Action and Apoptosis
|
ELFERINK, CORNELIS
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$299,918
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K01DK067207-04
|
|
Genetic Epidemiology of NAFLD and T2DM
|
KAO, WEN HONG
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$128,958
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI069952-03
|
|
Statistical methods for modeling hepatitis C fibrosis progression
|
BACCHETTI, PETER
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$178,477
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK051041-11
|
|
Genetics of Autosomal Dominant Polycystic Liver Disease
|
SOMLO, STEFAN
|
YALE UNIVERSITY
|
CT
|
$458,671
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
1R01CA126807-01A1
|
|
HCV genetic variation and hepatocellular carcinoma
|
TAVIS, JOHN
|
SAINT LOUIS UNIVERSITY
|
MO
|
$274,523
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
2R01AA012897-07A1
|
|
Effects of Ethanol TNF Induced Cytotoxicity
|
PASTORINO, JOHN
|
UNIV OF MED/DENT NJ-SCH OSTEOPATHIC MED
|
NJ
|
$259,350
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK056669-07
|
|
Transcriptional control in hepatocyte proliferation
|
GREENBAUM, LINDA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$316,418
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA100882-05
|
|
Molecular Pathogenesis of Hepatocellular Carcinoma
|
ROBERTS, LEWIS
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$258,035
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA013395-07
|
|
Ethanol Hepatotoxicity and NO-Dependent Mitochondrial Dysfunction
|
DARLEY-USMAR, VICTOR
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$294,638
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI068090-03
|
|
Understanding Immunopathogenesis of Hepatitis B Virus
|
BARON, JODY
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$367,527
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R01DK073897-01A2
|
|
Iron-Induced Changes in Liver That Predispose to Malignancy
|
ISOM, HARRIET
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$245,493
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
2R01DK056598-23
|
|
Metabolism of Glycerolipids in Liver
|
COLEMAN, ROSALIND
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$312,375
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R01DK078187-01A1
|
|
LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM
|
FINCK, BRIAN
|
WASHINGTON UNIVERSITY
|
MO
|
$304,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R01DK075990-01A2
|
|
Nutrition and Nonalcoholic Fatty Liver Disease
|
LI, ZHIPING
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$348,500
|
|
Chronic Liver Disease and Cirrhosis
|
NIDA
|
5R01DA010164-12
|
|
The Logics for HIV Risk Among Homeless Heroin Injectors
|
BOURGOIS, PHILIPPE
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$360,811
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA011593-09
|
|
Mg2+ homeostasis in liver cells treated with EtOH
|
ROMANI, ANDREA
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$244,808
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA013868-06
|
|
Egr1: A candidate molecular target for treating ALD.
|
NAGY, LAURA
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
OH
|
$292,988
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
2R01CA086978-06A1
|
|
Molecular mechanism of diet induced carcinogenesis
|
JACOB, SAMSON
|
OHIO STATE UNIVERSITY
|
OH
|
$302,115
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK068361-03
|
|
Role of immature DC in host defense against HCV
|
ANTHONY, DONALD
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$241,111
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5U01CA120475-02
|
|
The Role of mTOR Signaling in Hepatocellular Carcinogenesis
|
KOZMA, SARA
|
UNIVERSITY OF CINCINNATI
|
OH
|
$296,400
|
|
Chronic Liver Disease and Cirrhosis
|
NIBIB
|
5R01EB002132-06
|
|
Quantifying Liver Fibrosis with Acoustic Radiation Force
|
NIGHTINGALE, KATHRYN
|
DUKE UNIVERSITY
|
NC
|
$459,720
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK060719-06
|
|
ABC-transporter binding proteins and trafficking
|
ORTIZ, DANIEL
|
TUFTS UNIVERSITY BOSTON
|
MA
|
$255,156
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK045334-15
|
|
Regulation of Hepatic Glutathione Synthesis
|
LU, SHELLY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$266,573
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK051719-12
|
|
REGULATION OF METHIONINE ADENOSYLTRANSFERASE IN LIVER
|
LU, SHELLY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$317,971
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK069558-03
|
|
Purinergic Regulation of hepatocyte proliferation
|
THEVANANTHER, SUNDARARAJAH
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$263,351
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
1R01AI073335-01A2
|
|
RNA-dependent RNA Synthesis by the Hepatitis C Virus
|
KAO, CHENG
|
TEXAS A&M UNIVERSITY SYSTEM
|
TX
|
$287,713
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R21DK077961-01A1
|
|
dnTGF Beta RII Mice and PBC
|
LIAN, ZHE-XIONG
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$190,000
|
|
Chronic Liver Disease and Cirrhosis
|
NCCAM
|
1R21AT002895-01A2
|
|
Mechanisms of Action of Silymarin for Hepatitis C
|
POLYAK, STEPHEN
|
UNIVERSITY OF WASHINGTON
|
WA
|
$247,685
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI018641-26
|
|
Hepadnavirus Infections and Liver Cancer
|
MASON, WILLIAM
|
INSTITUTE FOR CANCER RESEARCH
|
PA
|
$562,151
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5F32DK079860-02
|
|
Characterization of the Assembly and Egress Pathway of Hepatitis C Virus
|
SHOHDY, NADIM
|
ROCKEFELLER UNIVERSITY
|
NY
|
$49,646
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K01DK078025-02
|
|
Modulators of liver injury
|
LEU, JULIE I-JU
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$116,623
|
|
Chronic Liver Disease and Cirrhosis
|
NIDA
|
1K23DA022454-01A1
|
|
Directly Observed Hepatitis C Treatment in Methadone Clinics
|
LITWIN, ALAIN
|
YESHIVA UNIVERSITY
|
NY
|
$178,897
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R01DK075635-01A2
|
|
Toll like receptor - Mediated pathways in liver injury
|
SZABO, GYONGYI
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$345,313
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R03DK075416-02
|
|
Relationship of metabolic abnormalities to hepatic steatosis in HIV
|
STERLING, RICHARD
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$72,290
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK075397-02
|
|
Potential Mechanisms of Glucagon-like peptide-1 in Fatty Liver Disease
|
ANANIA, FRANK
|
EMORY UNIVERSITY
|
GA
|
$253,399
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
1R21AA016301-01A2
|
|
Quantification of human alcohol metabolizing enzymes by mass spectrometry
|
BOSRON, WILLIAM
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$217,243
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
1K25CA127524-01A1
|
|
Biomarker Discovery for Hepatitis C Progression using Machine Learning Techniques
|
SPRATT, HEIDI
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$126,357
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI073299-02
|
|
Mechanism and in vivo anti-HBV study of a novel class of non-nucleoside compounds
|
CHENG, YUNG-CHI
|
YALE UNIVERSITY
|
CT
|
$365,024
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
1R21CA127046-01A1
|
|
Analysis of the Cytokine-Immunological Model of a Cancer-Related Symptom Cluster
|
STEEL, JENNIFER
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$204,525
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R01DK078686-01A1
|
|
Genetic and epigenetic regulation of Hepatitis B contributes to liver cancer
|
TORBENSON, MICHAEL
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$348,500
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R21DK077575-02
|
|
Liver Disease Associated with HCV/HIV Coinfection Due to TRAIL
|
VLAHAKIS, STACEY
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$181,300
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA010541-15
|
|
Role of Acetaldehyde on PDGF-BB-induced HSC Migration and Proliferation.
|
ROJKIND, MARCOS
|
GEORGE WASHINGTON UNIVERSITY
|
DC
|
$315,697
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA118165-02
|
|
Role of inflammation in tumor promotion and progression
|
KARIN, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$450,258
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R01DK077704-01A2
|
|
Viral Hepatitis C and Lipid Homeostasis
|
SIDDIQUI, ALEEM
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$328,313
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K23DK062116-04
|
|
Hyperinsulinemia and Insulin Resistance in Fatty Liver
|
ABDELMALEK, MANAL
|
DUKE UNIVERSITY
|
NC
|
$123,390
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K24DK002727-09
|
|
Cirrhosis and its complications
|
GARCIA-TSAO, GUADALUPE
|
YALE UNIVERSITY
|
CT
|
$156,104
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R21CA122523-02
|
|
Role of metallothioneins in hepatocellular carcinoma
|
JACOB, SAMSON
|
OHIO STATE UNIVERSITY
|
OH
|
$150,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI047347-10
|
|
Regulation of human T-cell immunity to HCV antigens
|
ECKELS, DAVID
|
UNIVERSITY OF UTAH
|
UT
|
$455,271
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA112053-04
|
|
Mechanisms of the HBX-interacting protein (HBXIP)
|
REED, JOHN
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
CA
|
$357,678
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK069859-03
|
|
Genes Related to HCC Progression in LD and DD Transplant
|
FISHER, ROBERT
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$482,550
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI065256-03
|
|
Antiretroviral Therapy and the Hepatitis C Virus
|
SHERMAN, KENNETH
|
UNIVERSITY OF CINCINNATI
|
OH
|
$686,648
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI066209-03
|
|
Viral Host Interactions in Hepatitis C
|
GRETCH, DAVID
|
UNIVERSITY OF WASHINGTON
|
WA
|
$408,680
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K23DK064909-05
|
|
Complications of Cirrhosis in American Patients
|
MARRERO, JORGE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$132,300
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA014428-05
|
|
Homocysteine, ER stress and alcoholic liver injury
|
KAPLOWITZ, NEIL
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$347,744
|
|
Chronic Liver Disease and Cirrhosis
|
NIEHS
|
5R01ES004139-18
|
|
Neutrophils and Hepatotoxicity
|
ROTH, ROBERT
|
MICHIGAN STATE UNIVERSITY
|
MI
|
$273,008
|
|
Chronic Liver Disease and Cirrhosis
|
NHLBI
|
5R01HL079381-05
|
|
Neutralizing Antibodies to Hepatitis C
|
FOUNG, STEVEN
|
STANFORD UNIVERSITY
|
CA
|
$589,711
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R21DK077694-01A1
|
|
STRATEGIC TARGETING OF VIRAL GENOMES IN BILIARY ATRESIA
|
SHEPHERD, ROSS
|
WASHINGTON UNIVERSITY
|
MO
|
$152,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI050798-05
|
|
Functional analysis of hepatitis C virus glycoproteins
|
MCKEATING, JANE
|
UNIVERSITY OF BIRMINGHAM
|
UK
|
$200,490
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK069757-04
|
|
Pathophysiology and Characterisation of NAFLD
|
CHARLTON, MICHAEL
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$294,078
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA055578-13
|
|
Role of PreS2 Mutants in Pathogenesis of Chronic Hepatitis B
|
YEN, TIEN-SZE
|
NORTHERN CALIFORNIA INSTITUTE RES & EDUC
|
CA
|
$245,449
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R21CA124493-02
|
|
Role of thyroid hormone receptor mutants in hepatocellular carcinoma
|
PRIVALSKY, MARTIN
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$178,486
|
|
Chronic Liver Disease and Cirrhosis
|
NHLBI
|
5R01HL055638-12
|
|
Assembly and Secretion of ApoB Containing Lipoproteins
|
GINSBERG, HENRY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$402,500
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA042715-22
|
|
Cellular Origins of Liver Cancer
|
HIXSON, DOUGLAS
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$288,011
|
|
Chronic Liver Disease and Cirrhosis
|
NIDA
|
5K01DA017179-05
|
|
HCV Treatment Cost-Effectiveness in 3 IDU Populations
|
SCHACKMAN, BRUCE
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$169,492
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK072187-02
|
|
Genetics of Nonalcoholic Fatty Liver Disease (NAFLD)
|
ERICKSON, SANDRA
|
NORTHERN CALIFORNIA INSTITUTE RES & EDUC
|
CA
|
$308,896
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK058123-08
|
|
TGF-beta, matrix, and myofibroblasts in hepatic fibrosis
|
WELLS, REBECCA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$316,418
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R37DK039588-21
|
|
MECHANISMS AND PATHOGENESIS OF PRIMARY BILIARY CIRRHOSIS
|
GERSHWIN, MERRILL
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$361,600
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK074768-03
|
|
THE PATHOGENESIS OF AUTOIMMUNITY IN A MURINE MODEL OF PRIMARY BILIARY CIRRHOSIS
|
GERSHWIN, MERRILL
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$539,843
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
1R21CA126137-01A2
|
|
Predicting Radiation Liver Injury Using MRI Perfusion
|
CAO, YUE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$208,575
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI072012-02
|
|
New Antiviral Therapies for Hepatitis C Infection
|
HERMANN, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$367,061
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
2R42CA121506-02
|
|
HCC diagnostics defined by fucosylated serum biomarkers
|
MEHTA, ANAND
|
IMMUNOTOPE, INC.
|
PA
|
$564,986
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R43DK080549-01
|
|
TGFb1 Receptor Inhibitors for Liver Fibrosis
|
CAI, WEIZHONG
|
ANGION BIOMEDICA CORPORATION
|
NY
|
$255,501
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R21AI066957-02
|
|
Immunity of neoantigen response in HCV, HIV, and HCV-HIV
|
ANTHONY, DONALD
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$189,456
|
|
Chronic Liver Disease and Cirrhosis
|
NICHD
|
5R01HD024455-19
|
|
Regulation of Fetal Hepatic Growth
|
GRUPPUSO, PHILIP
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$341,180
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
1R41CA132397-01
|
|
Small Molecule Inhibitors of HBV/HCV Induced Liver Diseases
|
DHEER, SURENDRA
|
SONITU PHARMACEUTICALS, LLC
|
PA
|
$168,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
2R44DK074205-02
|
|
Novel diagnostic and safety biomarkers of liver injury and hepatotoxicity
|
SVETLOV, STANISLAV
|
BANYAN BIOMARKERS, INC.
|
FL
|
$422,483
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK053792-08
|
|
Liver Disease in Obesity
|
DIEHL, ANNA MAE
|
DUKE UNIVERSITY
|
NC
|
$336,285
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK075128-03
|
|
MR Imaging of Non-Alcoholic Fatty Liver Disease
|
SIRLIN, CLAUDE
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$463,288
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK054488-08
|
|
FUNCTION OF THE HEMOCHROMATOSIS PROTEIN
|
ENNS, CAROLINE
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$404,883
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA037232-24
|
|
HEPADNAVIRUS ASSOCIATED HEPATOCELLULAR CARCINOMA
|
ROGLER, CHARLES
|
YESHIVA UNIVERSITY
|
NY
|
$483,550
|
|
Chronic Liver Disease and Cirrhosis
|
NIBIB
|
5R01EB005964-03
|
|
Monitoring Hepatitis and Cirrhosis by 23Na MRS/MRI
|
BANSAL, NAVIN
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$380,683
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA016003-02
|
|
Mechanisms of CTGF-Induced Liver Disease
|
BRIGSTOCK, DAVID
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$324,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
1R43AI074214-01A1
|
|
An RNAi Trojan Horse for treatment of hepatitis C.
|
JOHNSTON, BRIAN
|
SOMAGENICS, INC.
|
CA
|
$295,743
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK037948-22
|
|
OBESITY AND NONALCOHOLIC FATTY LIVER DISEASE
|
KLEIN, SAMUEL
|
WASHINGTON UNIVERSITY
|
MO
|
$430,721
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
1P01AA017103-01
|
9001
|
Administrative Core
|
MCCLAIN, CRAIG
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$450,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA008714-17
|
|
ALCOHOL AND THE CONTROL OF LIVER REGENERATION
|
HOEK, JOANNES
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$334,944
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA003624-29
|
|
Control of drug and ethanol metabolism
|
ARTEEL, GAVIN
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$258,674
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
1R13AI077295-01
|
|
Hepatic Inflammation and Immunity 2008
|
LEMON, STANLEY
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$20,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R13AI077295-01
|
|
Hepatic Inflammation and Immunity 2008
|
LEMON, STANLEY
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$5,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK059935-07
|
|
Acyl-CoA Synthetase: Structure, Function and Regulation
|
COLEMAN, ROSALIND
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$290,896
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R43AI072780-02
|
|
Broadly Neutralizing MAbs against Hepatitis C Virus
|
OLSON, WILLIAM
|
PROGENICS PHARMACEUTICALS, INC.
|
NY
|
$287,309
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K24DK066306-04
|
|
POR In Inherited Metabolic Liver Diseases
|
MISTRY, PRAMOD
|
YALE UNIVERSITY
|
CT
|
$151,526
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K23DK077568-02
|
|
Kidney Disease in HIV-Hepatitis C Virus Co-Infection
|
WYATT, CHRISTINA
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$129,225
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI068769-03
|
|
QUALITATIVE NATURE OF ANTIBODIES TO HCV GLYCOPROTEIN SUBUNIT VACCINE IN HUMANS
|
RAY, RANJIT
|
SAINT LOUIS UNIVERSITY
|
MO
|
$315,056
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA124488-02
|
|
Cell Penetrating Peptide Inhibitor of FoxM1 in Hepatocellular Carcinoma Treatment
|
RAYCHAUDHURI, PRADIP
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$286,458
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA067529-14
|
|
Helicobacter induced hepatitis and tumorigenesis
|
FOX, JAMES
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$341,346
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK050697-11
|
|
The Genetic Basis of Cholestasis
|
BULL, LAURA
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$291,125
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK074959-03
|
|
Novel Therapies for Metabolic Complications in Patients with Lipodystrophies
|
GARG, ABHIMANYU
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$320,688
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R21CA122317-02
|
|
Development of Glypican-3 as a biomarker for hepatocellular carcinoma
|
SO, SAMUEL
|
STANFORD UNIVERSITY
|
CA
|
$146,400
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA085888-09
|
|
Malignant Complications of Chronic HCV
|
LOFFREDO, CHRISTOPHER
|
GEORGETOWN UNIVERSITY
|
DC
|
$297,351
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK056621-09
|
|
The Role of KLF6 in Hepatic Fibrosis
|
FRIEDMAN, SCOTT
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$346,505
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA014257-04
|
|
Lymphocyte recruitment in alcoholic hepatitis
|
ADAMS, DAVID
|
UNIVERSITY OF BIRMINGHAM
|
UK
|
$153,605
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK066368-05
|
|
Genetic Modifiers of CF Liver Disease
|
KNOWLES, MICHAEL
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$614,590
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA016171-03
|
|
Quantitative Proteomic Analysis of Alcoholic Fatty Liver Biogenesis
|
WU, CHRISTINE
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$293,024
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA113447-03
|
|
DNA Repair of Endogenous Lesions in Carcinogenesis
|
ROY, RABINDRA
|
GEORGETOWN UNIVERSITY
|
DC
|
$290,517
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK066754-05
|
|
Impaired T cell function by HCV core
|
HAHN, YOUNG
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$282,304
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R21CA121553-02
|
|
Hepatic Arterial Flouridine and IV Bevacizumab for Primary Hepatic Malignancy
|
JARNAGIN, WILLIAM
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$312,246
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K24DK078154-02
|
|
Epidemiology and Outcomes of Digestive and Liver Diseases: A Mentoring Program
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$149,057
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI049574-08
|
|
GBV-B: A Small Primate Model for Hepatitis C Infection
|
LANFORD, ROBERT
|
SOUTHWEST FOUNDATION FOR BIOMEDICAL RES
|
TX
|
$311,605
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI060449-05
|
|
Liver Disease and HIV-HBV Coinfection in the HAART era
|
THIO, CHLOE
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$587,069
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA122434-03
|
|
Role of the Putative Tumor Suppressor PinX1 in the Etiology of Liver Cancer
|
ZHOU, XIAO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$293,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R21AA016316-02
|
|
Alcoholic Hepatitis: Molecular Mechanisms
|
SAFE, STEPHEN
|
TEXAS A&M UNIVERSITY SYSTEM
|
TX
|
$169,918
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK047995-13
|
|
Inhibition of hepatic stellate cell activation
|
CHEN, ANPING
|
SAINT LOUIS UNIVERSITY
|
MO
|
$286,759
|
|
Chronic Liver Disease and Cirrhosis
|
NIMH
|
1R21MH078740-01A2
|
|
Enhancing HCV Treatment Decisions in HIV Co-Infected Patients and Their Providers
|
WAGNER, GLENN
|
RAND CORPORATION
|
CA
|
$238,108
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK059580-08
|
|
Molecular Physiology of Hepatic Transport
|
GREEN, RICHARD
|
NORTHWESTERN UNIVERSITY
|
IL
|
$251,456
|
|
Chronic Liver Disease and Cirrhosis
|
NIDA
|
5R01DA022177-02
|
|
Opioids, HIV/HCV and Host Cell Innate Immunity
|
HO, WENZHE
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$402,864
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R03DK076583-02
|
|
Notch Signaling and Cell Fate in Embryonic and Adult Liver
|
STANGER, BEN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$77,175
|
|
Chronic Liver Disease and Cirrhosis
|
NIDA
|
1K01DA024654-01
|
|
Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients
|
PILLAI, SATISH
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$180,360
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
2R01AI052065-05A2
|
|
HCV and HIV Progression in Women on HAART
|
KOVACS, ANDREA
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$533,057
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R21DK074891-02
|
|
Novel model of HCV infection of humanized liver in immunocompetent rats
|
WU, GEORGE
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
CT
|
$145,040
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5F32DK076342-02
|
|
Abcb11 and Hepatic Transport
|
HENKEL, ANNE
|
NORTHWESTERN UNIVERSITY
|
IL
|
$61,202
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK070849-04
|
|
Regulation of Bile Ductular Proliferation
|
DRANOFF, JONATHAN
|
YALE UNIVERSITY
|
CT
|
$311,451
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK053224-09
|
|
CXC chemokines and liver regeneration
|
COLLETTI, LISA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$310,489
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA111427-05
|
|
Early antibody markers of HCC
|
FEITELSON, MARK
|
TEMPLE UNIVERSITY
|
PA
|
$276,457
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA113663-04
|
|
Hepatitis B ESL Education for Chinese
|
TAYLOR, VICTORIA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$400,747
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK074627-02
|
|
Nonalcoholic steatohepatitis and Cytochrome P450 Enzymes
|
CHALASANI, NAGA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$244,154
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK074538-02
|
|
Fibronectin deposition and TGF-beta activation in liver fibrosis
|
SAKAI, TAKAO
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
OH
|
$302,820
|
|
Chronic Liver Disease and Cirrhosis
|
NIEHS
|
5K22ES012978-03
|
|
Endogenous Radicals, Hepatic Lipid Peroxidation, and ALD
|
QIAN, STEVEN
|
NORTH DAKOTA STATE UNIVERSITY
|
ND
|
$105,840
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA109574-04
|
|
RNAi-Based Therapy of Hepatocellular Carcinoma
|
LI, KAIYI
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$224,720
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R01DK080670-01
|
|
Genomics of Primary Biliary Cirrhosis
|
LAZARIDIS, KONSTANTINOS
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$300,894
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5K01CA107092-05
|
|
Hepatocellular carcinoma: targeting HCV replication
|
LINDENBACH, BRETT
|
YALE UNIVERSITY
|
CT
|
$162,378
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R37CA035711-25
|
|
Pathogenesis, Immunodiagnosis and Therapy of HCC
|
WANDS, JACK
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$320,011
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA008116-15
|
|
Lipid Peroxidation in Alcoholic Liver Disease
|
FRENCH, SAMUEL
|
LA BIOMED RES INST/ HARBOR UCLA MED CTR
|
CA
|
$311,797
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA111456-04
|
|
The impact of growth modulation of liver carcinogenesis
|
YIN, XIAO-MING
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$272,640
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA014623-04
|
|
Zinc and Alcohol-Induced Oxidative Liver Injury
|
ZHOU, ZHANXIANG
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$270,054
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK070844-03
|
|
Transplantation of Reduced-Size Fatty Livers
|
ZHONG, ZHI
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$256,328
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R21CA128391-02
|
|
Randomized trial of doxorubicin beads for arterial embolization of hepatocellular
|
BROWN, KAREN
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$187,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K24DK002755-10
|
|
Studies of Mechanisms and Treatment of Liver Diseases
|
SANYAL, ARUN
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$146,447
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5F32DK074307-03
|
|
PPARgamma-Cofactor Interactions in Fibrotic Liver
|
DWYER, MARY
|
DUKE UNIVERSITY
|
NC
|
$52,048
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK038652-21
|
|
Hepatic Fibrosis: Molecular Mechanisms
|
CHOJKIER, MARIO
|
VETERANS MEDICAL RESEARCH FDN/SAN DIEGO
|
CA
|
$315,322
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K01DK067933-05
|
|
NO production and S-nitrosylation in liver vasculature
|
IWAKIRI, YASUKO
|
YALE UNIVERSITY
|
CT
|
$136,755
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA100830-06
|
|
Oncolytic VSV for Hepatocellular Carcinoma
|
WOO, SAVIO
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
NY
|
$338,076
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5F31AA016863-02
|
|
Role of Cellular Fibronectin in the Promotion of Alcohol-Induced Liver Injury
|
AZIZ-SEIBLE, RAZIA
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$28,405
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K08DK071940-04
|
|
wnt Signaling in Liver Development and Disease
|
GOESSLING, WOLFRAM
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$134,730
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
1R25CA129042-01A1
|
|
Asian American Liver Cancer Education Program in Maryland
|
JUON, HEE-SOON
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$276,609
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K23DK068290-05
|
|
Genetic Epidemiology of Primary Biliary Cirrhosis
|
LAZARIDIS, KONSTANTINOS
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$126,335
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K08DK067187-05
|
|
The Role of Lymphotoxin Receptor in Liver Regeneration
|
ANDERS, ROBERT
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$134,730
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI063795-04
|
|
Living Cell Arrays for Real Time Functional Genomics
|
YARMUSH, MARTIN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$664,697
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R24AA012885-08
|
|
Non-parenchymal Liver Cell Core
|
TSUKAMOTO, HIDEKAZU
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$314,685
|
|
Chronic Liver Disease and Cirrhosis
|
NIDA
|
5R01DA020841-03
|
|
Hepatitis Care Coordination in Methadone Treatment
|
PERLMAN, DAVID
|
BETH ISRAEL MEDICAL CTR (NEW YORK)
|
NY
|
$354,372
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5K23AI065319-04
|
|
Thrombocytopenia & HIV/HCV: Risk Factors & Treatment
|
MARKS, KRISTEN
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$131,490
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5K08AI069989-02
|
|
An in vitro system to study antiviral strategies against Hepatitis C virus
|
WYLES, DAVID
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$105,570
|
|
Chronic Liver Disease and Cirrhosis
|
NIDA
|
5R01DA020781-03
|
|
Hepatitis Care Coordination in Methadone Treatment
|
MASSON, CARMEN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$331,144
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R03DK080715-01
|
|
The Role of NOX2 in Liver Fibrosis
|
TOROK, NATALIE
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$76,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK074718-02
|
|
Evaluation of MRI & MR Spectroscopic Markers in Non-Alcoholic Fatty Liver Disease
|
QAYYUM, ALIYA
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$217,273
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5R01AI047519-10
|
|
Cellular immunity - outcome hepatitis C virus infection
|
CHANG, KYONG-MI
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$304,162
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK075830-02
|
|
The Endocannabinoid System in hepatic Injury and Fibrosis
|
SCHWABE, ROBERT
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$258,759
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R01CA112481-04
|
|
STEM CELLS AND HEPATOCARCINOGENESIS
|
SELL, STEWART
|
ORDWAY RESEARCH INSTITUTE, INC.
|
NY
|
$255,805
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R01DK080852-01
|
|
Liver regeneration with stems cells of uniparental origin
|
MCLAUGHLIN, KENNETH
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$345,579
|
|
Chronic Liver Disease and Cirrhosis
|
NIGMS
|
5R01GM061834-07
|
|
Acetaminophen Pharmacogenetics
|
COURT, MICHAEL
|
TUFTS UNIVERSITY BOSTON
|
MA
|
$286,125
|
|
Chronic Liver Disease and Cirrhosis
|
NCI
|
5R21CA125321-02
|
|
Variation in NTP use by the HCV polymerase and response to therapy
|
TAVIS, JOHN
|
SAINT LOUIS UNIVERSITY
|
MO
|
$147,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R01DK080765-01
|
|
Functional investigation of hemojuvelin in regulation of hepcidin expression
|
ZHANG, AN-SHENG
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$226,897
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
1R01DK080711-01
|
|
Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
|
FAN, XIAOFENG
|
SAINT LOUIS UNIVERSITY
|
MO
|
$294,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R42AA014554-03
|
|
Transgenic plant cells as a source of hepatoprotective drugs
|
LITTLETON, JOHN
|
NAPROGENIX, INC
|
KY
|
$249,230
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R21DK078100-02
|
|
Ribavirin Pharmacokinetics, Race and HCV Treatment
|
HOWELL, CHARLES
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$181,912
|
|
Chronic Liver Disease and Cirrhosis
|
NCRR
|
5R01RR006555-17
|
|
Modeling Viral and T Lymphocyte Dynamics
|
PERELSON, ALAN
|
LOS ALAMOS NAT SECTY-LOS ALAMOS NAT LAB
|
NM
|
$307,697
|
|
Chronic Liver Disease and Cirrhosis
|
NIAID
|
5K08AI072191-02
|
|
Mechanisms of T cell dysfunction in Hepatitis C virus persistence
|
RADZIEWICZ, HENRY
|
EMORY UNIVERSITY
|
GA
|
$128,250
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5K08DK072858-04
|
|
Pathogenic Mechanisms of Virus Induced Biliary Atresia
|
TIAO, GREGORY
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$125,820
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK078857-02
|
|
Interferon modulation of cellular microRNAs in the Hepatitis C antiviral defense
|
DAVID, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$279,351
|
|
Chronic Liver Disease and Cirrhosis
|
NIAAA
|
5R01AA015970-04
|
|
S-adenosylhomocysteine and S-adenosylmethionine in Alcoholic Liver Disease
|
MCCLAIN, CRAIG
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$334,478
|
|
Chronic Liver Disease and Cirrhosis
|
OD
|
5R01AA015970-04
|
|
S-adenosylhomocysteine and S-adenosylmethionine in Alcoholic Liver Disease
|
MCCLAIN, CRAIG
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$60,000
|
|
Chronic Liver Disease and Cirrhosis
|
NIDDK
|
5R01DK075274-02
|
|
Mouse model of chronic viral hepatitis
|
CRISPE, IAN
|
UNIVERSITY OF ROCHESTER
|
NY
|
$306,368
|
|
